La Trobe

GPA33 is expressed on multiple human blood cell types and distinguishes CD4+ central memory T cells with and without effector function

journal contribution
posted on 2025-11-07, 02:16 authored by R Opstelten, JS Suwandi, MC Slot, F Morgana, Andrew ScottAndrew Scott, S Laban, T Nikolic, AW Turksma, A Kroeze, C Voermans, JJ Zwaginga, BO Roep, D Amsen
<p dir="ltr">Abstract:</p><p dir="ltr">The Ig superfamily protein glycoprotein A33 (GPA33) has been implicated in immune dysregulation, but little is known about its expression in the immune compartment. Here, we comprehensively determined GPA33 expression patterns on human blood leukocyte subsets, using mass and flow cytometry. We found that GPA33 was expressed on fractions of B, dendritic, natural killer and innate lymphoid cells. Most prominent expression was found in the CD4<sup>+</sup> T cell compartment. Naïve and CXCR5<sup>+</sup> regulatory T cells were GPA33<sup>high</sup>, and naïve conventional CD4<sup>+</sup> T cells expressed intermediate GPA33 levels. The expression pattern of GPA33 identified functional heterogeneity within the CD4<sup>+</sup> central memory T cell (Tcm) population. GPA33<sup>+</sup> CD4<sup>+</sup> Tcm cells were fully undifferentiated, <i>bona fide</i> Tcm cells that lack immediate effector function, whereas GPA33<sup>–</sup> Tcm cells exhibited rapid effector functions and may represent an early stage of differentiation into effector/effector memory T cells before loss of CD62L. Expression of GPA33 in conventional CD4<sup>+</sup> T cells suggests a role in localization and/or preservation of an undifferentiated state. These results form a basis to study the function of GPA33 and show it to be a useful marker to discriminate between different cellular subsets, especially in the CD4<sup>+</sup> T cell lineage.</p>

Funding

This work was partly supported by grants from the Landsteiner Foundation for Blood Cell Research to DA (LSBR 1430, LSBR 1818). J.S. and B.R. are financed by the Dutch Diabetes Research Foundation and Foundation DON (Expert Center Grant, 2013.40.1693), T.N. and J.J.Z. are financed by the Dutch Arthritis Foundation (Research Center of Excellence program, LLP-16). A.K. was supported by Sanquin Research (PPOC13-027 grant). A Fellowship from the Landsteiner Foundation for Blood Transfusion Research to CV (grant no. #1101) also supported part of this work. A.M.S. is supported by an NHMRC Investigator Grant (No: 1177837).

Molecular Imaging and Therapy of Cancer

National Health and Medical Research Council

Find out more...

History

Publication Date

2021-06-07

Journal

European Journal of Immunology

Volume

51

Issue

6

Pagination

13p. (p. 1377-1389)

Publisher

Wiley

ISSN

0014-2980

Rights Statement

© 2021 The Authors. European Journal of Immunology published by Wiley-VCH GmbH This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Usage metrics

    Journal Articles

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC